This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [01.11.2019] – [general research on aging] sallieq | home:food:aim_health:aging [02.24.2019] – [Recent studies showed] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== | + | ====== |
Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
Line 8: | Line 8: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
- | Benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. (({{pubmed> | + | Although uncontrolled confounding might still exist, (//this was a short term study//) olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed> |
- | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | + | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> |
- | Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared | + | Benefits of RAS blockade |
- | The ROADMAP study will answer | + | Data demonstrate potential benefits of reducing |
- | The data demonstrate potential benefits | + | Administration |
+ | |||
+ | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) | ||
+ | |||
+ | Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats. (({{pubmed> | ||
+ | |||
+ | Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease | ||
+ | |||
+ | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | ||
+ | |||
+ | Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
+ | |||
+ | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
- | Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
==== General research on aging ==== | ==== General research on aging ==== | ||
- | Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, | + | Holistic vitamin D supplementation with or without calcium |
+ | When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. | ||
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| | ||
Line 31: | Line 43: | ||
* inhibit liver fibrosis and aid liver healing(({{pubmed> | * inhibit liver fibrosis and aid liver healing(({{pubmed> | ||
* reduce insulin resistance in rats(({{pubmed> | * reduce insulin resistance in rats(({{pubmed> | ||
- | * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed> | + | |
* protect the mitochondria from age-associated damage from oxidation(({{pubmed> | * protect the mitochondria from age-associated damage from oxidation(({{pubmed> | ||
* play a protective role against proliferative diabetic retinopathy (({{pubmed> | * play a protective role against proliferative diabetic retinopathy (({{pubmed> | ||
Line 82: | Line 94: | ||
=== A number of studies have found === | === A number of studies have found === | ||
- | that olmesartan | + | that olmesartan |
* in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | * in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | ||
* in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | ||
- | * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed> | + | * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis |
* renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | ||
* olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | ||
Line 92: | Line 104: | ||
- | === Recent studies | + | === Studies also showed === |
Line 109: | Line 121: | ||
=== Long term treatment === | === Long term treatment === | ||
- | Data suggest 40 & 80 mg olmesartan | + | |
// | // | ||
{{tag> | {{tag> | ||